I like “Parkinson-like.”

Does anyone like being called “atypical”?  That adjective often conveys a foreign-ness or other-ness, and not in a good way.  If you agree, you will be glad to know that a colleague, Dr. Junaid Siddiqui of the Cleveland Clinic, and I are about to publish an opinion piece entitled, “Time to Retire the Term “Atypical Parkinsonism.”

Over my career as a movement disorders subspecialist, I’ve heard both from professional colleagues and my patients that the term “atypical Parkinsonism” for PSP, CBD, MSA and a few other conditions is unwelcome.  First, it implies that those conditions are simply unusual variants of Parkinson’s disease.  However, they are actually independent diseases at the microscopical, molecular, and clinical levels with some features in common with PD.  A similar problem applies to the term “Parkinson-plus.”  PSP, CBD, and MSA aren’t simply PD with some additional features. 

Yes, those three disease do include some degree of “Parkinsonism,” but that only means that they share a collection of outward slowness, muscle rigidity, impaired balance, and in some cases, tremor. Of course, the Parkinsonism of PSP, CBD, and MSA differ from that of PD.  But that’s not because the first three are atypical versions of the fourth – it’s because they’re fundamentally different diseases.  

That’s the scientific argument, but there’s also an emotional one.  As I mentioned at the outset, no one wants their uncommon disorder to be considered an appendage of some other, more frequent one with superficial similarities.  That would suggest that the uncommon condition is unworthy of its own approaches to support, treatment, and scientific study.  

So, Dr. Siddiqi and I propose replacing the terms “atypical Parkinsonism,” “atypical Parkinsonian disorder,” and “Parkinson-plus disorder” with “Parkinson-like disorder.”  This avoids the implication of inferiority and other-ness without losing the “Parkinson” term familiar to every physician.

The “-like” term has precedent in “Huntington-like disorder,” “polio-like syndrome,” and “stroke-like syndrome,” and that’s only in neurology.  Yes, changing medical language can be a heavy lift, but it’s been done before.  Examples just in movement disorders are Steele-Richardson-Olszewski syndrome to PSP, paralysis agitans to Parkinson’s disease, striatonigral degeneration to MSA-Parkinson, sporadic olivopontocerebellar ataxia to MSA-cerebellar, and corticodentatonigral degeneration to corticobasal degeneration.

Glossary of proposed terminology:

ExistingProposedDefinition/comments
Parkinson’s diseaseParkinson’s diseaseNo change proposed
parkinsonismParkinsonismA group of phenotypic features, not specific disease(s).  The first letter should be upper-case.
ParkinsonismsParkinsonian disorderMultiple members of a group of specific disorders featuring Parkinsonism
Primary parkinsonismPrimary Parkinsonian disorderAny neurodegenerative disorder featuring Parkinsonism as a major component, at least in a majority of cases
Secondary parkinsonismSecondary Parkinsonian disorderAny non-degenerative disorder featuring Parkinsonism in at least some cases or at some point in the illness
Atypical Parkinsonism or typical Parkinsonian disorderParkinson-like disorderReserve “Parkinsonism” for a group of phenotypic features.  Reserve “Parkinson-like” for specific diseases. Replace “Parkinson-plus” with “Parkinson-like disorder” as well.

Our paper will appear in the journal Parkinsonism and Related Disorders in a few days or weeks, at which time I’ll post you a link.  Of course, if the journal itself follows our recommendation to confine the term “Parkinsonism” to a collection of signs and symptoms rather than allowing it to refer to specific diseases, then it will have to change its own name!  But — one step at a time, I always tell my students and patients.

14 shots on goal coming up

Time for my occasional update on current and upcoming neuroprotection trials for PSP. The tables here are slides from a lecture I gave a few days ago on that topic at the University of Chicago.

This first table shows trials that have completed patient recruitment but for which there are no available results. This is usually because the analysis is incomplete or some of the patients are still having their study visits, but in a few cases it’s for the company’s own business reasons.

The second table shows PSP trials currently recruiting or likely to start doing so in the next year or two. Note that the trial of selenium supplementation, in the first row, is happening only in Australia. The only one recruiting anywhere else right now is FNP-223. If you’re interested in enrolling in that one, call the sponsor company in Spain at +34 609 850 565 or email them at medinfo@ferrer.com. They can tell you which of their study sites is closest to your home and then you’d contact that site’s coordinator directly.

Note that the GV1001 trial is presently only in South Korea, but the company says it will come to the US in late 2025.

Also note that the AZP-2006 and AADvac1 trials are the first two of what will soon be three drugs in the PSP Trial Platform. The third will be announced soon and the trial is scheduled to get under way in late 2025.

If you’re thinking of volunteering for a trial, do it sooner rather than later. Several reasons:
• The drug is more likely to work in earlier-stage PSP.
• The trials all require participants to have no more than a certain level of symptom severity and duration.
• If you insist on waiting for the perfect drug trial, you will be waiting a long time!